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Introduction
============

Alcohol use disorders (AUD) are debilitating psychiatric illnesses characterized by the abuse of and dependence on alcohol. The lifetime prevalence of AUD is estimated to be at 29.1%. AUD bring about devastating consequences to the individual. They are associated with a high disease-related burden -- chronic alcohol consumption is causally implicated in cancer, cardiovascular disease, liver cirrhosis, and injury. On top of that, an estimated 3.8% of deaths and 4.6% of disability life years are attributable to alcohol. At the societal level, the economic costs associated with AUD amounts to at least 1% of the gross national product in high and middle-income countries. Given such consequences, the need to treat AUD cannot be understated. Ever since naltrexone was approved as a treatment for alcohol dependence in 1994 by the U.S. Federal Drug Administration, it has been widely used as a first-line pharmacological treatment for AUD. As a μ-opioid receptor antagonist, naltrexone blocks alcohol-related dopamine release in the mid-brain reward system, thereby reducing the reward and reinforcement associated with alcohol consumption.

Many controlled trials have been carried out over the past three decades to examine the efficacy of naltrexone on various AUD-related outcomes and several meta-analyses have been carried out to synthesize the results of these studies. These meta-analyses have generally indicated moderate to strong efficacy in treating AUD with naltrexone. However, these meta-analyses included studies that carried out various psychotherapies to augment the naltrexone treatment of AUD. Two studies \[[@REF1], [@REF2]\] had previously examined the effect of adding psychotherapy to naltrexone treatment in treating AUD, within-study, and concluded that adding psychotherapy to the naltrexone treatment of AUD did not result in significantly better outcomes. Apart from these two studies, it remains largely unclear if the significant treatment effect is primarily attributed to naltrexone alone or the combination of naltrexone and psychotherapy. Such information would be useful to optimize existing naltrexone interventions on AUD.

To this end, in addition to examining the overall efficacy of naltrexone on AUD, we also examined the impact of psychotherapy in two different ways. First, we compared the pooled estimates between studies with and without psychotherapy; then we examined the moderation effect of psychotherapy on the treatment outcomes. As with previous meta-analyses on AUD intervention studies, we hypothesized that the meta-analysis would yield significant effect sizes favoring the use of naltrexone on AUD. Additionally, based on a previous meta-analysis comparing between pharmacological-only treatment and combined psychotherapy and pharmacological treatment, we hypothesized that studies of naltrexone treatment combined with psychotherapy yield significantly better AUD-related outcomes relative to those of naltrexone alone studies.

Materials and methods
=====================

Data sources and extraction

Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology, a search for relevant published literature was carried out on PubMed, Medline and Cochrane using the keywords "naltrexone", "low dose naltrexone", "high dose naltrexone", "naltrexone alcohol", "naltrexone psychotherapy". This search started on 2nd February 2017 and was last carried out on 30th March 2017. The reference lists of relevant studies were also manually searched for additional studies. Only articles in English were retrieved. We included studies of controlled trials involving naltrexone treatment on AUD. Specifically, these studies must be of an independent group\'s pretest-posttest design. There were no restrictions on patients' age or level of alcohol use. Researches that studied AUD-related outcomes using experimental/laboratory paradigms were not included in the meta-analysis.

Means and standard deviations (SD) as well as event counts of the trial outcomes, and information pertaining to the participants (sample size, age, sex, diagnosis), and trial-design (naltrexone dose, duration and psychotherapy) for each study were entered into a structured data abstraction form by the two research assistants. If there were discrepancies among both of them, the entered data was checked against the source. In cases, where there were multiple naltrexone treatment groups (i.e., different dosages), these means, SDs and event counts of these groups were combined using the formulae for combining groups. Due to the multitude of outcomes studied among the retrieved studies, only data from outcomes, which have been reported by at least four studies in each of the with and without psychotherapy subgroups, were extracted. For the purpose of the current study, we define psychotherapy as non-pharmacological treatment, such as individual and group therapy, psychoeducation, counseling and skills training, of at least two sessions, aimed at modifying cognition and/or behaviors associated with alcohol consumption. Hence, interventions that focused solely on adherence or medication compliance are not considered as psychotherapy. The flow chart for the selection of studies and data extraction is shown in Figure [1](#FIG1){ref-type="fig"}.
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Data Synthesis

For outcomes involving dichotomous variables only at post-treatment, such as the number of participants who relapsed to heavy drinking or remained abstinent, the log Odds Ratios (OR) and their respective sampling variance were calculated using the escalc function in the metafor package in R. As for continuous outcomes studied both at baseline and post-treatment such as Gamma-Glutamyl Transferase (GGT) levels and cravings, the raw score single group pretest-posttest standardized mean difference (SMD) for both the treatment and placebo groups was computed separately using Formula A1. Following which, the placebo group's SMD was subtracted from that of the treatment group to obtain the overall SMD for a particular studied outcome in the study. The sampling variances of the treatment and placebo subgroups were then summed to obtain the overall sampling variance for that outcome in the study.

These SMDs and ORs were then pooled and meta-analyzed using random effects models (REM), to allow the effect sizes to vary across studies. The direction of the effect sizes was coded in a manner that larger positive effect sizes correspond to larger positive differences (i.e., treatment -- placebo) in raw scores. The Wald test was used to compare the pooled estimates between studies with and without psychotherapy. Next, a mixed effects model was meta-analyzed with psychotherapy (coded dichotomously for presence or absence) included as a moderator. Heterogeneity was measured using the Q statistic; a significant Q statistic suggests that the variability among the effect sizes is larger than what is expected from subject sampling error alone. In addition, trim and fill analyses were carried out to assess whether publication bias had significantly influenced the aggregated effect sizes. Specifically, the trim and fill analyses determine whether there are missing effect sizes, if so impute the missing effect sizes, and then recalculate the aggregated effect sizes. Follow-up leave-one-out analyses were carried out to assess the robustness of the results. These analyses were carried out using the metafor package in R 3.4.0.

Results
=======

The study and participant characteristics of all included studies are presented in Table [1](#TAB1){ref-type="table"} and Table [2](#TAB2){ref-type="table"}, respectively. At least four studies in each of the with or without psychotherapy subgroups had reported data on abstinence, relapse, cravings, and GGT; these variables were then included in the meta-analyses. The results of the meta-analysis are shown in Table [3](#TAB3){ref-type="table"}. The forest plots for the REMs of all studies are presented in Figures [2](#FIG2){ref-type="fig"}-[5](#FIG5){ref-type="fig"}. Significant pooled estimates were obtained for the REM involving studies with psychotherapy for abstinence and relapse and all studies, for abstinence, relapse, and GGT. The significant negative effect sizes for relapse and GGT, and positive effect size for abstinence indicated that participants in the naltrexone treatment conditions had significantly better outcomes in these areas, relative to those in the placebo group. With the exception of a significant intercept in the mixed effect model (MEM) for relapse, none of the parameters in the MEMs was significant for any of the studied outcomes. Neither were the effect sizes in any of the craving meta-analyses statistically significant. Finally, none of the Wald test statistics was significant, suggesting that the pooled estimates of studies with and without psychotherapy were not significantly different.

###### Study characteristics of included studies.

d/d = drinks per day; d/o = drinks per occasion; dd/w = drinking days per week; BAC = Breath Alcohol Concentration; OCDS = Obsessive Compulsive Drinking scale; AUQ = Alcohol Urge Questionnaire; PACS = Penn Alcohol Craving Scale.

  ------------------------------- ---------------------- ---------------------------------------------------------------------- ------------------------------------------------ --------------------------- --------------------------------------------------- -----------------------
  [Study]{.ul}                    [Psychotherapy]{.ul}   [Treatment dosage]{.ul}                                                [Trial duration]{.ul}                            [Relapse definition]{.ul}   [Measures of cravings]{.ul}                         
  First author                    Year                                                                                                                                                                                                                            
  Anton et al. \[[@REF3]\]        2006                   No psychotherapy                                                       100 mg/day                                       16 weeks                    ≥4 drinks/day for women; ≥5 d/d for men             OCDS
  Anton et al. \[[@REF4]\]        2003                   Cognitive behavioral therapy                                           50 mg/day                                        12 weeks                                                                        Analog scale
  Anton et al. \[[@REF3]\]        2006                   Combined behavioral intervention                                       100 mg/day                                       16 weeks                    ≥4 d/d for women; ≥5 d/d for men                    OCDS
  O\'Malley et al. \[[@REF5]\]    1992                   Coping skills                                                          50 mg/day                                        12 weeks                    ≥4 d/o for women; ≥5 d/o for men                     
  O\'Malley et al. \[[@REF5]\]    1992                   Supportive therapy                                                     50 mg/day                                        12 weeks                                                                         
  Oslin et al. \[[@REF6]\]        1997                   Group therapy                                                          50 mg/day                                        12 weeks                    ≥ 5 d/occasion OR ≥ 5 dd/w or BAC \> 100 mg/dl       
  Petrakis et al. \[[@REF7]\]     2005                   No psychotherapy                                                       50 mg/day                                        12 weeks                                                                         
  Volpicelli et al. \[[@REF8]\]   1997                   Relapse prevention                                                     50 mg/day                                        12 weeks                    ≥ 5 d/o or BAC \>100 mg/dl                           
  Davidson et al. \[[@REF9]\]     2004                   Counseling                                                             50 mg/day                                        10 weeks                                                                         
  Kranzler et al. \[[@REF10]\]    2000                   Relapse prevention psychotherapy                                       50 mg/day                                        11 weeks                                                                         
  Monti et al. \[[@REF11]\]       2001                   Coping skills training and communication skills training               50 mg/day                                        12 weeks                    \>5 d/d for women; \>6 d/d for men                   
  O\'Malley et al. \[[@REF12]\]   2003                   No psychotherapy                                                       50 mg/day                                        24 weeks                                                                        OCDS
  O\'Malley et al. \[[@REF12]\]   2003                   Cognitive behavioral therapy                                           50 mg/day                                        24 weeks                                                                        OCDS
  O\'Malley et al. \[[@REF13]\]   2008                   No psychotherapy                                                       1 x 12.5 mg + 2 x 25 mg + 50 mg/day thereafter   16 weeks                    ≥4 d/d for women; ≥5 d/d for men                    AUQ
  Oslin \[[@REF14]\]              2005                   No psychotherapy                                                       50 mg/day                                        12 weeks                    ≥3 d/d for women; ≥4 d/d for men                     
  Pettinati et al. \[[@REF15]\]   2006                   Cognitive behavioral therapy                                           50 mg/day                                        11 weeks                                                                         
  Brown et al. \[[@REF16]\]       2009                   Cognitive behavioral therapy                                           50 mg/day                                        12 weeks                                                                        PACS
  Anton et al. \[[@REF2]\]        2005                   Cognitive behavioral therapy                                           50 mg/day                                        12 weeks                    ≥4 d/d for women; ≥5 d/d for men                     
  Anton et al. \[[@REF2]\]        2005                   Motivational enhancement therapy                                       50 mg/day                                        12 weeks                    ≥4 d/d for women; ≥5 d/d for men                     
  Kranzler et al. \[[@REF17]\]    2004                   Motivational enhancement therapy                                       300 mg + 3 months x 150 mg injection             12 weeks                    ≥4 d/d for women; ≥5 d/d for men                    OCDS
  Pettinati et al. \[[@REF18]\]   2010                   Cognitive behavioral therapy                                           100 mg/day                                       14 weeks                    ≥4 d/d for women; ≥5 d/d for men                     
  Baltieri et al. \[[@REF19]\]    2008                   Relapse prevention counseling                                          50 mg/day                                        12 weeks                                                                        OCDS
  Guardia et al. \[[@REF20]\]     2002                   Supportive group therapy: relapse prevention + individual counseling   50 mg/day                                        12 weeks                    \>5 d/d for men; \>4 d/d for women; or \> 5dd/w     11-point Likert scale
  Kiefer et al. \[[@REF21]\]      2003                   Group therapy: cognitive behavioral model of substance abuse           50 mg/day                                        12 weeks                    ≥5 d/d for men; ≥4 d/d for women; or ≥5 dd/w        OCDS
  Morley et al. \[[@REF22]\]      2006                   No psychotherapy                                                       50 mg/day                                        12 weeks                    ≥4 d/d for women; ≥6 d/d for men                    PACS
  Balldin et al. \[[@REF23]\]     2003                   Cognitive behavioral therapy                                           50 mg/day                                        6 months                    ≥4 d/d for women; ≥5 d/d for men                    OCDS
  Balldin et al. \[[@REF23]\]     2003                   Supportive therapy                                                     50 mg/day                                        6 months                    ≥4 d/d for women; ≥5 d/d for men                    OCDS
  Chick et al. \[[@REF24]\]       2000                   Psychosocial treatment                                                 50 mg/day                                        12 weeks                    ≥ 5 d/o for men; ≥ 4 d/o for women                   
  Heinala et al. \[[@REF25]\]     2001                   Coping (group therapy)                                                 50 mg/day                                        12 weeks                    ≥ 5 d/o or ≥ 5 dd/w or intoxication at site visit    
  Heinala et al. \[[@REF25]\]     2001                   Supportive therapy                                                     50 mg/day                                        12 weeks                    ≥ 5 d/o OR ≥ 5 dd/w or intoxication at site visit    
  Ahmadi et al. \[[@REF1]\]       2004                   Counseling                                                             50 mg/day                                        36 weeks                    ≥ 5 d/o or ≥ 5 dd/w                                  
  Gastpar et al. \[[@REF26]\]     2002                   Psychosocial treatment                                                 50 mg/day                                        12 weeks                    ≥4 d/d for women; ≥5 d/d for men                     
  Morris et al. \[[@REF27]\]      2001                   Psychoeducation                                                        50 mg/day                                        12 weeks                    ≥ 5 d/occasion or ≥ 5 dd/w or BAC \> 100 mg/dl       
  Latt et al. \[[@REF28]\]        2002                   Counseling and supportive therapy                                      50 mg/day                                        12 weeks                    ≥ 5 dd/w                                            OCDS
  Toneatto et al. \[[@REF29]\]    2009                   Cognitive behavioral therapy                                           3 x 25 mg +11 x 50 mg                            12 weeks                                                                         
  Krystal et al. \[[@REF30]\]     2001                   Counseling                                                             2 x 25 mg + 50 mg/day thereafter                 3 months                    ≥4 d/d for women; ≥6 d/d for men                     
  ------------------------------- ---------------------- ---------------------------------------------------------------------- ------------------------------------------------ --------------------------- --------------------------------------------------- -----------------------

###### Participant characteristics of included studies.

AUD = Alcohol use disorders; DSM = Diagnostic and Statistic Manual; SD = Standard Deviation; C = Coping; CBT = Cognitive Behavioral Therapy; ST = Supportive Therapy; NP = No psychotherapy; AD = Alcohol Dependence; AD/A = Alcohol dependence or abuse; AUDIT = Alcohol Use Disorder Inventory Test; MET = Motivational Enhancement Therapy; CBI = Combined Behavioral Intervention.

  ------------------------------------- --------------- ---------------------------------------- ------------ ---------- ----------- --------- ------- ------- ------- -------
  [Study]{.ul}                          AUD diagnosis   [Number of participants (% male)]{.ul}   [Age]{.ul}                                                            
  Baseline                              Follow Up       Treatment                                Control                                                               
  First author                          Year                                                     Treatment    Placebo    Treatment   Placebo   Mean    SD      Mean    SD
  Anton et al. \[[@REF4]\]              2003            DSM-III-R AD                             68 (69)      63 (73)    68          63        41      10      44      10
  Anton et al. \[[@REF3]\] (CBI)        2006a           DSM-IV AD                                155 (68)     156 (71)   95          100       45.2    10.1    43.2    9.7
  Anton et al. \[[@REF3]\] (NP)         2006a           DSM-IV AD                                154 (68)     103 (67)   96          89        44.4    9.9     44.2    9.2
  O\'Malley et al. \[[@REF5]\] (C)      1992            DSM-III-R AD                             29           25         19          15        42.8    10.3    38.5    8.8
  O\'Malley et al. \[[@REF5]\] (ST)     1992            DSM-III-R AD                             23           27         18          16                                 
  Oslin et al. \[[@REF6]\]              1997            DSM-III-R AD                             21           23         14          13        56.5    6.8     58.9    6.7
  Petrakis et al. \[[@REF7]\]           2005            DSM-IV AD                                59 (100)     64 (100)   46          40        47.7    7.4     46.2    7.3
  Volpicelli et al. \[[@REF8]\]         1997            DSM-III-R AD                             48 (73)      49 (82)    35          36        39      9       37.9    8.5
  Davidson et al. \[[@REF9]\]           2004            AUDIT ≥ 8                                19           19         16          19        46.5    10.5    50.8    7
  Kranzler et al. \[[@REF10]\]          2000            DSMIII-R AD                              61 (80)      63 (75)                          39.7    8.4     41.8    8.1
  Monti et al. \[[@REF11]\]             2001            DSM-IV AD/A                              64           64                                                        
  O\'Malley et al. \[[@REF12]\] (NP)    2003            DSM-III-R AD                             26           27         17          13                                 
  O\'Malley et al. \[[@REF12]\] (CBT)   2003            DSM-III-R AD                             30           30         19          24                                 
  O\'Malley et al. \[[@REF13]\]         2008            DSM-IV AD                                34 (65)      34 (62)    35          21        42      10.67   38.8    10.41
  Oslin \[[@REF14]\]                    2005            DSM-IV AD                                37 (78)      37 (81)                          64.2    6.9     62.5    5.6
  Pettinati et al. \[[@REF15]\]         2006            DSM-IV AD                                52 (75)      54 (70)    35          32        41.3    6.8     41.2    7.5
  Brown et al. \[[@REF16]\]             2009            DSM-IV AD                                20 (50)      20 (45)    14          12                                 
  Anton et al. \[[@REF2]\] (CBT)        2005            DSM-IV AD                                39 (79)      41 (73)    36          37        44      8       45      11
  Anton et al. \[[@REF2]\] (MET)        2005            DSM-IV AD                                41 (73)      39 (77)    34          28        43      10      43      9
  Kranzler et al. \[[@REF17]\]          2004            DSM-IV AD                                158 (67)     157 (63)   127         118       44.1    9.6     43.6    8.5
  Pettinati et al. \[[@REF18]\]         2010            DSM-IV AD                                49 (67)      39 (56)    29          23        42.9    8.1     43.4    8.9
  Baltieri et al. \[[@REF19]\]          2008            ICD-10 AD                                49 (100)     54 (100)   29          23        44.1    7.2     43.4    8.8
  Guardia et al. \[[@REF20]\]           2002            DSM-IV AD                                101 (72)     101 (77)   61          59        41      8       42      9
  Kiefer et al. \[[@REF21]\]            2003            DSM-IV AD                                40 (78)      40 (68)    22          10        46.1    8.1     45.6    11.1
  Morley et al. \[[@REF22]\]            2006            DSM-IV AD/A                              53 (72)      61 (64)    36          40        47.6    8.5     42.4    9.3
  Balldin et al. \[[@REF23]\] (CBT)     2003            DSM-IV AD                                25 (84)      30 (77)                          50      7       50      8
  Balldin et al. \[[@REF23]\] (ST)      2003            DSM-IV AD                                31 (87)      32 (91)                          48      8       51      8
  Chick et al. \[[@REF24]\]             2000            DSM-III-R AD/A                           90 (72)      85 (78)    37          36        43.1    8.3     43.9    9.7
  Heinala et al. \[[@REF25]\] (C)       2001            DSM-IV AD                                34           33                                                        
  Heinala et al. \[[@REF25]\] (ST)      2001            DSM-IV AD                                29           25                                                        
  Ahmadi et al. \[[@REF1]\]             2004            DSM-IV AD                                58           58         26          15        42.76   9.58    43.19   8.81
  Gastpar et al. \[[@REF26]\]           2002            DSM-III-R AD/A                           84 (77)      87 (68)    56          54        43.4    9.9     42      9.6
  Morris et al. \[[@REF27]\]            2001            DSM-III-R AD                             55 (100)     56 (100)                         47      8       48      8
  Latt et al. \[[@REF28]\]              2002            DSM-IV AD                                56           51         38          36                                 
  Toneatto et al. \[[@REF29]\]          2009            DSM-IV AD/A                              27           25         26          25                                 
  Krystal et al. \[[@REF30]\]           2001            DSM-IV AD                                418 (97)     209 (98)   378         187       48.9    10      49.5    10
  ------------------------------------- --------------- ---------------------------------------- ------------ ---------- ----------- --------- ------- ------- ------- -------

###### Results of the meta-analyses.

Note: Estimates for REM in the abstinence and relapse models are presented as odds ratios.

K = Number of studies; CI = Confidence intervals; w/o = without; GGT = Gamma-Glutamyl Transferase; REM = Random Effects Model; MEM = Mixed Effects Model.

\*p \< .05; \*\*p \< .01; \*\*\*p \< .001.

  ----------------------------------------- ---- -------------- ------------ ----------- ------------ --------- ----------------------------------
  Model/Parameter                           K    N~treatment~   N~control~   Estimate    95% CI       Q         P~with\ vs.\ w/o\ psychotherapy~
  [Abstinence]{.ul}                                                                                              
  Random Effect Model (REM)                 17   954            959          1.36\*      1.06, 1.75   25.26      
  With psychotherapy                        13   771            763          1.45\*      1.10, 1.91   22.01     .43
  w/o psychotherapy                         4    183            196          1.10        .59, 2.06    5.69      
  Mixed Effect Model (MEM)                  17   954            959                                   27.70      
  Intercept                                                                  .07         -.47, .61               
  Psychotherapy                                                              .27         -.34, .88               
  [Relapse]{.ul}                                                                                                 
  REM                                       27   1990           1725         .66\*\*\*   .57, .77     40.33\*    
  With psychotherapy                        23   1656           1434         .65\*\*\*   .55, .77     35.59\*   .67
  w/o psychotherapy                         4    334            286          .70\*       -.68, .98    4.59      
  MEM                                       27   1990           1725                                  41.80\*    
  Intercept                                                                  -.35\*      -.69 -.02               
  Psychotherapy                                                              -.07        -.44, .30               
  [Gamma Glutamyl Transferase (GGT)]{.ul}                                                                        
  REM                                       13   554            565          -.16\*      -.29, -.04   3.74       
  With psychotherapy                        9    379            389          -.15        -.30, .01    2.37      .74
  w/o psychotherapy                         4    175            176          -.19        -.41, .03    1.26      
  MEM                                       13   554            565                                   3.29       
  Intercept                                                                  -.19        -.41, .03               
  Psychotherapy                                                              -.05        -.22, .32               
  [Cravings]{.ul}                                                                                                
  REM                                       14   626            640          -.11        -.31, .10    2.36       
  With psychotherapy                        10   457            467          -.19        -.42, .03    15.55     .14
  w/o psychotherapy                         4    169            173          .14         -.24, .51    4.42      
  MEM                                       14   626            640                                   23.38\*    
  Intercept                                                                  .14         -.23, .51               
  Psychotherapy                                                              -.33        -.76, .10               
  ----------------------------------------- ---- -------------- ------------ ----------- ------------ --------- ----------------------------------
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The Q statistics indicated that there was significant heterogeneity in the REMs of all studies and studies with psychotherapy for relapse. Furthermore, there was also significant heterogeneity in the MEMs for relapse, and cravings. The trim and fill analyses carried out for all REMs of all studies did not result in any imputation of studies. This suggests that publication biases were minimal or non-significant. The funnel plots and leave-one-out analyses are presented in Figures [6](#FIG6){ref-type="fig"}-[9](#FIG9){ref-type="fig"} and Tables [4](#TAB4){ref-type="table"}-[7](#TAB7){ref-type="table"}. In general, the exclusion of any single study from the REMs did not alter the statistical significance of any existing pooled estimates; these estimates remained statistically significant in the REMs for abstinence, relapse, and GGT, and non-significant in the REM for cravings. These results suggest that the results are generally robust.
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###### Leave-one-out sensitivity analysis for abstinence.

C = Coping; ST = Supportive Therapy.

  ---- ------------------------------------------ ---------- -------------- -------- ------ ------- --------
       Study/Year                                 Estimate   P­~Estimate~   95% CI   Q      P~Q~    
  1    O\'Malley et al. \[[@REF5]\] (C)(1992)     0.31       0.0227         0.04     0.57   25.22   0.0471
  2    O\'Malley et al. \[[@REF5]\] (ST) (1992)   0.24       0.0331         0.02     0.46   18.82   0.2220
  3    Oslin et al. \[[@REF6]\] (1997)            0.31       0.0209         0.05     0.58   25.26   0.0465
  4    Volpicelli et al. \[[@REF8]\] (1997)       0.31       0.0280         0.03     0.59   25.21   0.0472
  5    Anton et al. \[[@REF4]\] (2003)            0.29       0.0380         0.02     0.56   24.56   0.0562
  6    Kranzler et al. \[[@REF10]\] (2000)        0.35       0.0076         0.09     0.61   23.18   0.0803
  7    Chick et al. \[[@REF24]\] (2000)           0.34       0.0134         0.07     0.62   24.37   0.0591
  8    Morris et al. \[[@REF27]\] (2001)          0.29       0.0275         0.03     0.55   24.62   0.0552
  9    Gastpar et al. \[[@REF26]\] (2002)         0.34       0.0201         0.05     0.62   24.92   0.0511
  10   Kiefer et al. \[[@REF21]\] (2003)          0.25       0.0326         0.02     0.48   19.63   0.1867
  11   Kranzler et al. \[[@REF17]\] (2004)        0.27       0.0449         0.01     0.53   23.81   0.0683
  12   Petrakis et al. \[[@REF7]\] (2005)         0.34       0.0137         0.07     0.62   24.39   0.0588
  13   Oslin \[[@REF14]\] (2005)                  0.35       0.0068         0.10     0.6    22.76   0.0893
  14   Morley et al. \[[@REF22]\] (2006)          0.33       0.0149         0.07     0.6    24.71   0.0539
  15   O\'Malley et al. \[[@REF13]\] (2008)       0.26       0.0325         0.02     0.5    22.11   0.1048
  16   Baltieri et al. \[[@REF19]\] (2008)        0.33       0.0173         0.06     0.61   24.93   0.0509
  17   Pettinati et al. \[[@REF18]\] (2010)       0.34       0.0135         0.07     0.6    24.51   0.0570
  ---- ------------------------------------------ ---------- -------------- -------- ------ ------- --------

###### Leave-one-out sensitivity analysis for relapse.

C = Coping; ST = Supportive Therapy; CBI = Combined Behavioral Intervention; NP = No psychotherapy; CBT = Cognitive Behavioral Therapy; MET = Motivational Enhancement Therapy.

  ---- ------------------------------------------ ---------- -------------- -------- ------- ------- --------
       Study                                      Estimate   P­~Estimate~   95% CI   Q       P~Q~    
  1    O\'Malley et al. \[[@REF5]\] (C)(1992)     -0.44      \<.0001        -0.59    -0.29   33.74   0.1417
  2    O\'Malley et al. \[[@REF5]\] (ST) (1992)   -0.44      \<.0001        -0.58    -0.29   35.76   0.0961
  3    Anton et al. \[[@REF3]\] (CBI) (2006)      -0.44      \<.0001        -0.59    -0.28   41.27   0.0292
  4    Anton et al. \[[@REF3]\] (NP) (2006)       -0.42      \<.0001        -0.57    -0.27   41.95   0.0248
  5    Oslin et al. \[[@REF6]\] (1997)            -0.41      \<.0001        -0.56    -0.26   41.01   0.0310
  6    Volpicelli et al. \[[@REF8]\] (1997)       -0.41      \<.0001        -0.56    -0.26   41.42   0.0282
  7    Anton et al. \[[@REF4]\] (2003)            -0.39      \<.0001        -0.54    -0.24   40.09   0.0382
  8    Chick et al. \[[@REF24]\] (2000)           -0.41      \<.0001        -0.56    -0.26   41.96   0.0248
  9    Krystal et al. \[[@REF30]\] (2001)         -0.41      \<.0001        -0.58    -0.25   41.97   0.0247
  10   Heinala et al. \[[@REF25]\] (C)(2001)      -0.43      \<.0001        -0.58    -0.28   35.02   0.1111
  11   Heinala et al. \[[@REF25]\] (ST) (2001)    -0.42      \<.0001        -0.56    -0.27   41.94   0.0249
  12   Morris et al. \[[@REF27]\] (2001)          -0.41      \<.0001        -0.56    -0.26   41.94   0.0249
  13   Guardia et al. \[[@REF20]\] (2002)         -0.40      \<.0001        -0.55    -0.25   40.29   0.0366
  14   Gastpar et al. \[[@REF26]\] (2002)         -0.44      \<.0001        -0.59    -0.29   40.13   0.0379
  15   Latt et al. \[[@REF28]\] (2002)            -0.40      \<.0001        -0.55    -0.25   41.09   0.0304
  16   Kiefer et al. \[[@REF21]\] (2003)          -0.40      \<.0001        -0.55    -0.25   39.93   0.0396
  17   Balldin et al. \[[@REF23]\] (2003) (CBT)   -0.41      \<.0001        -0.56    -0.27   41.81   0.0257
  18   Balldin et al. \[[@REF23]\] (2003) (ST)    -0.42      \<.0001        -0.57    -0.28   40.26   0.0368
  19   Kranzler et al. \[[@REF17]\] (2004)        -0.41      \<.0001        -0.56    -0.26   41.79   0.0258
  20   Ahmadi et al. \[[@REF1]\] (2004)           -0.40      \<.0001        -0.55    -0.25   40.78   0.0326
  21   Oslin \[[@REF14]\] (2005)                  -0.43      \<.0001        -0.58    -0.28   40.76   0.0328
  22   Anton et al. \[[@REF2]\] (2005) (CBT)      -0.40      \<.0001        -0.55    -0.25   40.76   0.0328
  23   Anton et al. \[[@REF2]\] (2005) (MET)      -0.41      \<.0001        -0.56    -0.26   41.94   0.0249
  24   Morley et al. \[[@REF22]\] (2006)          -0.44      \<.0001        -0.59    -0.29   40.07   0.0384
  25   O\'Malley et al. \[[@REF13]\] (2008)       -0.41      \<.0001        -0.56    -0.26   41.15   0.0299
  26   Toneatto et al. \[[@REF29]\] (2009)        -0.41      \<.0001        -0.56    -0.26   40.33   0.0362
  27   Pettinati et al. \[[@REF18]\] (2010)       -0.42      \<.0001        -0.57    -0.28   41.56   0.0272
  28   Monti et al. \[[@REF11]\] (2001)           -0.42      \<.0001        -0.57    -0.27   41.89   0.0252
  ---- ------------------------------------------ ---------- -------------- -------- ------- ------- --------

###### Leave-one-out sensitivity analysis for Gamma-Glutamyl Transferase.

PCM = Primary Care Management; CBT = Cognitive Behavioral Therapy.

  ---- -------------------------------------------- ---------- -------------- -------- ------- ------ --------
       Study/Year                                   Estimate   P­~Estimate~   95% CI   Q       P~Q~   
  1    Anton et al. \[[@REF4]\] (2003)              -0.16      0.0203         -0.29    -0.02   3.74   0.9769
  2    Petrakis et al. \[[@REF7]\] (2005)           -0.16      0.0221         -0.29    -0.02   3.71   0.9777
  3    Volpicelli et al. \[[@REF8]\] (1997)         -0.15      0.0229         -0.28    -0.02   3.60   0.9802
  4    O\'Malley et al. \[[@REF12]\] (2003) (PCM)   -0.15      0.0243         -0.28    -0.02   2.94   0.9915
  5    O\'Malley et al. \[[@REF12]\] (2003) (CBT)   -0.17      0.0088         -0.30    -0.04   3.14   0.9887
  6    O\'Malley et al. \[[@REF13]\] (2008)         -0.17      0.0091         -0.30    -0.04   3.24   0.9871
  7    Brown et al. \[[@REF16]\] (2009)             -0.16      0.0125         -0.29    -0.03   3.71   0.9776
  8    Baltieri et al. \[[@REF19]\] (2008)          -0.15      0.0228         -0.28    -0.02   3.62   0.9798
  9    Kiefer et al. \[[@REF21]\] (2003)            -0.16      0.0170         -0.29    -0.03   3.73   0.9772
  10   Balldin et al. \[[@REF23]\] (2003) (CBT)     -0.16      0.0125         -0.29    -0.04   3.69   0.9781
  11   Balldin et al. \[[@REF23]\] (2003) (ST)      -0.15      0.0231         -0.28    -0.02   3.27   0.9867
  12   Morris et al. \[[@REF27]\] (2001)            -0.18      0.0065         -0.32    -0.05   2.59   0.9951
  13   Latt et al. \[[@REF28]\] (2002)              -0.15      0.0207         -0.29    -0.02   3.68   0.9783
  ---- -------------------------------------------- ---------- -------------- -------- ------- ------ --------

###### Leave-one-out sensitivity analysis for cravings.

PCM = Primary Care Management; CBT = Cognitive Behavioral Therapy.

  ---- -------------------------------------------- ---------- -------------- -------- ------ ------- --------
       Study/Year                                   Estimate   P­~Estimate~   95% CI   Q      P~Q~    
  1    Anton et al. \[[@REF4]\] (2003)              -0.09      0.4124         -0.31    0.13   22.94   0.0282
  2    Davison et al. \[[@REF9]\] (2004)            -0.14      0.1903         -0.34    0.07   21.14   0.0484
  3    Kranzler et al. \[[@REF10]\] (2000)          -0.05      0.6108         -0.23    0.13   17.18   0.1430
  4    O\'Malley et al. \[[@REF12]\] (2003) (PCM)   -0.11      0.3018         -0.33    0.10   23.28   0.0254
  5    O\'Malley et al. \[[@REF12]\] (2003) (CBT)   -0.12      0.2539         -0.34    0.09   22.72   0.0302
  6    O\'Malley et al. \[[@REF13]\] (2008)         -0.09      0.4202         -0.30    0.13   22.70   0.0304
  7    Brown et al. \[[@REF16]\] (2009)             -0.08      0.4584         -0.28    0.12   20.37   0.0603
  8    Baltieri et al. \[[@REF19]\] (2008)          -0.11      0.3152         -0.32    0.10   23.36   0.0249
  9    Guardia et al. \[[@REF20]\] (2002)           -0.12      0.2898         -0.35    0.10   22.61   0.0312
  10   Kiefer et al. \[[@REF21]\] (2003)            -0.11      0.3106         -0.33    0.11   23.29   0.0253
  11   Morley et al. \[[@REF22]\] (2006)            -0.15      0.1115         -0.35    0.04   18.49   0.1016
  12   Balldin et al. \[[@REF23]\] (2003) (CBT)     -0.06      0.5330         -0.26    0.13   19.46   0.0779
  13   Balldin et al. \[[@REF23]\] (2003) (ST)      -0.10      0.3821         -0.32    0.12   23.24   0.0258
  14   Latt et al. \[[@REF28]\] (2002)              -0.13      0.1999         -0.34    0.07   21.49   0.0437
  ---- -------------------------------------------- ---------- -------------- -------- ------ ------- --------

Discussion
==========

The current study examined the hypothesis that naltrexone is efficacious in treating AUD and psychotherapy on top of naltrexone significantly augments AUD-related treatment outcomes. In relation to former, our results have generally indicated that naltrexone has been efficacious in treating AUD. Specifically, the pool estimates indicated significant treatment effects in improving self-reported alcohol consumption outcomes such as abstinence, relapse as well as the objectively measured GGT, which is a widely used and highly specific biomarker for excessive alcohol consumption. However, there was not a significant treatment effect on cravings. In relation to the second hypothesis, adding psychotherapy to the naltrexone treatment of AUD did not significantly augment treatment outcomes; the combined treatment of psychotherapy and naltrexone was not significantly better than naltrexone alone.

The non-significant difference in treatment outcomes between studies with and without psychotherapy is noteworthy considering that previous meta-analytic research had found combined treatments significantly more effective than pharmacological treatment alone in treating mood and anxiety disorders. Nevertheless, while previous meta-analyses have noted significant and large treatment effects associated with psychotherapy among these affective disorders, psychotherapy has been less successful with AUDs. Meta-analyses have generally reported small and non-significant treatment effects associated with psychotherapy on AUD. Given these weak effects, one would not expect the addition of psychotherapy to significantly augment the naltrexone treatment of AUD. Indeed, researchers who investigated such a hypothesis within-study did not find significant differences between combined treatment and naltrexone-only treatment in influencing subsequent AUD outcomes \[[@REF2], [@REF3]\]. One may be concerned at the large variety of psychotherapies carried out across studies, thus rendering it difficult to interpret or generalize these results to the different adjunctive psychotherapies. This may be the case for the meta-analyzed relapse outcome, which was associated with significant heterogeneity. Notwithstanding the slight variation in the definition of relapse across studies, it may be possible that certain therapies when combined with naltrexone yield much better treatment outcomes than others. Nevertheless, despite the wide variety of psychotherapies carried out across the different studies, the results among studies with psychotherapy were not significantly heterogeneous, at least in relation to abstinence, GGT and cravings. Assuming the naltrexone effect is constant across study, this may hint to the dodo bird verdict -- all psychotherapies, regardless of their theoretical orientations, produced similar outcomes. Regardless, future researchers may consider comparing treatment outcomes between various psychotherapies in combination with naltrexone to verify such an interpretation.

It is also interesting that while naltrexone had resulted in significantly improved treatment outcomes in terms of self-reported measures and biomarkers of alcohol consumption, it did not seem to have a significant treatment effect in reducing alcohol-related cravings. There may be two explanations for this. First, while naltrexone reportedly modulates the dopaminergic activity in the mid-brain reward system in an attempt to inhibit the reinforcement associated with alcohol consumption, it does little to alleviate alcohol-related cravings which are largely associated with activity in the prefrontal and limbic regions of the brain. Second, it is plausible that alcohol-related cravings will decrease on its own even without any naltrexone treatment and this decrease will therefore mask the naltrexone treatment effect, if any at all on cravings. Indeed, we observed that several studies reported significant decreases (with respect to baseline) in cravings among placebo groups which were comparable to those of the naltrexone treatment groups. Furthermore, this decrease cannot be explained by the adjunctive psychotherapy in most of the included studies since it was not a significant moderator in the MEM; the pooled estimates relating to the decrease in cravings were also similar between studies with and without psychotherapy.

These findings present a key implication in the treatment of AUD. These results suggest that it is not necessary for adjunctive psychotherapy to be carried out on top of naltrexone in the treatment of AUD. From a resource-allocation perspective, given that individual psychotherapy is a relatively time- and resource-consuming process, the resources associated with such adjunctive psychotherapies can be conserved, or instead should be directed at other clinical populations, such as those with depression and anxiety disorders, in which psychotherapy would be a lot more beneficial.

The current results are subjected to three major limitations. Firstly, given the very limited number of studies on naltrexone treatment without psychotherapy, their pooled estimates may not reliably reflect the effect of naltrexone treatment alone. More 'naltrexone-only' intervention studies should be carried out such that future meta-analyses can robustly compare the AUD treatment outcomes between combined-intervention and naltrexone-only treatments. Secondly, it is possible that between-study differences in methodology or participants' characteristics among the included studies may confound the inclusion of psychotherapy in influencing treatment outcomes. Future intervention studies on AUD should be carried out to examine the inclusion of psychotherapy on top of naltrexone treatment within-study, such that stronger conclusions relating to the addition of psychotherapy on top of naltrexone can be made. Thirdly, the manner in which the additive effects of psychotherapy were studied in the current meta-analysis was less than optimal, given that we have simply compared studies with or without psychotherapy, instead of studies with psychotherapy or a control condition for psychotherapy. Furthermore, unlike the naltrexone condition, the psychotherapy conditions were not randomly assigned across all participants. This might raise concerns relating to whether psychotherapy effects were genuine or attributable to psychotherapy-placebo effects. Finally, as a result of our study inclusion criteria, such as English language studies only and including outcomes studied by three studies without therapy, we excluded a large number of studies, including one with a large sample. This creates a selection bias and may raise concerns relating to the generalizability of the results.

Conclusions
===========

Naltrexone treatment is efficacious in reducing alcohol consumption, but not reducing cravings. Adding psychotherapy on top naltrexone did not result in any significant additional benefit for AUD patients.
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